P&G Health to expand its VMS portfolio, injectables production

livemint.com:

NEW DELHI : Procter & Gamble Health Ltd, a subsidiary of the multinational consumer goods firm Procter & Gamble, is preparing to expand its portfolio of vitamins, minerals, and supplements (VMS), especially neurotrophic vitamins, under its five-year plan, Milind Thatte, MD of the company, said. The company has a portfolio that comprises 90% of VMS products, with nasal decongestant Nasivision accounting for the remainder. “We are constantly upgrading our portfolio offerings and have launched four different products in the last three to four years.

And so, we will continue to launch more and more products in the market as upgrades of the currently available formulations and others as additional offerings. These expansion plans come as part of our five-year vision that we have for our portfolio," Thatte told Mint. The company has set aside funds to continue innovating and elevating its growth trajectory in the country, Thatte said, without disclosing the exact amount.

The company said it currently holds a strong position in various subcategories of VMS. It says it has a market share of around 80% in vitamin E supplements, is a pioneer in big complex therapies, and in marketing neurotrophic vitamins. The company’s portfolio includes well-established brands like Livogen, Evion, Neurobion Polybion, and Seven Seas.